Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Molécula pequeña innovadora de fase clínica primera en su categoría para el tratamiento del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20180810001
Publicado:
10/04/2019
Caducidad:
23/10/2019
Resumen:
Una compañía farmacéutica clínica francesa especializada en oncología ha descubierto y está desarrollando nuevos agentes anticancerígenos. Estos agentes trabajan mediante un mecanismo de acción original que lleva a la muerte de las células cancerosas. Con este nuevo mecanismo de acción, la empresa está desarrollando medicamentos para el cáncer de hígado y tiene el potencial para desarrollar medicamentos contra diferentes tipos de tumores. La molécula pequeña utiliza un nuevo mecanismo de acción que induce la dishomeostasis de zinc en células cancerosas, actuando también en células madre cancerosas (CSC), y mostrando un tropismo sobre el hígado natural. La empresa busca socios con el fin de establecer acuerdos de financiación, joint venture y licencia para entrar en el sector sanitario.

Details

Tittle:
Innovative clinical stage small molecule for liver cancer
Summary:
A French clinical pharmaceutical company has discovered and is developing new anticancer agents.These agents act on the lysosomal compartment of cancer cells, including on cancer stem cells. With this promising mechanism of action, they are developing drugs for liver cancers and have the potential to develop drugs against a range of tumor types. They are searching for joint venture agreement with companies from the Healthcare sector abroad, with a distribution license agreement eventually.
Description:
The French pharmaceutical company is developing a new oral small molecule targeting the lysosomal compartment of cancer cells, including cancer stem cells.

In vitro data confirmed the anti-cancer agent action on many tumor types (colon carcinoma, pancreatic cancer, renal cell carcinoma, acute myeloid leukemia and melanoma).
In vivo studies confirmed the efficiency of this drug-candidate in primary liver cancers. Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the most common primary liver cancers and their incidence is expected to keep progressing due to the poor lifestyle, population ageing (most cases are on people over 60 years old) and exposure to chemicals.

In Europe and US, intrahepatic cholangiocarcinoma (iCCA) is an orphan disease, allowing the French company to benefit from the Orphan Drug Designation (ODD) in these two regions (submission ongoing) and to benefit from a breakthrough innovation status.
For Western countries, their strategy is to bring their special molecule to market as the first approved second-line treatment in iCCA (then go up to first line). Their anti-cancer agent will then be also indicated in second-line treatment for HCC.

In addition, the company´s ambition is to extend the indication of their anti-cancer agents in other cancer types (lung, pancreas, colon, prostate cancers, glioblastoma, melanoma, sarcoma) once the recommended dose is determined.
Eventually, they are also exploring the potential of their molecule as an anticancer agent in trans-arterial chemoembolization to treat the intermediate stage of HCC.

They are actively researching partners to support their most advanced specific anti-cancer agent development on the market. They are opened to financial agreement (VC, Bank, Private Investors).
They are also searching for joint venture agreement with companies from the Healthcare sector abroad, with a distribution license agreement eventually.

Advantages and Innovations:
The anti-cancer agent developed by this French company is different from other compounds indicated in primary liver cancers in the market but also from current drugs in hepatocellular carcinoma (HCC) pipeline in many aspects :

- First-of-all, this is the first time that a lysosomotropic agent reaches clinical stage in primary liver cancer.

- With its mechanism of action, this drug-candidate has the potential to be combined with any other anticancer drugs.
The molecule can be associated with any other anticancer therapy, including immunotherapies.

- In vitro, current anti-cancer chemotherapeutics primarily target proliferating cancer cells and are not effective against cancer stem cells (CSC). The new molecule shows an action against all tumour subpopulations including subpopulations displaying high resistance such as CSC in primary and metastatic liver cancers. Indeed, most cells within the tumor can regenerate through their stem-cell-like behaviour after treatment. For this reason, innovative treatment which could tackle CSC offers great promise for cancer treatment and prevention of relapse.

- Its chemical and physical properties make it an excellent candidate for oral formulation, with a high bioavailability and a better patients´ quality of life. Its high liver affinity makes it a treatment of choice in liver malignancies, also reducing the undesirable effects.
Stage of Development:
Field tested/evaluated
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
A patent protecting this molecule, its manufacturing, pharmaceutical composition, and use as a drug for the treatment of proliferative diseases was filed in 2014. This patent is currently examined at international level (PCT procedure).
The active pharmaceutical ingredient is protected by a patent and with an US provisional application allowing to claim priority date (October 31th, 2014).
The patent is currently in national and regional phases in more than 44 countries and regions. Mainly, the patent is granted in Europe, and examined in Canada, USA, Australia, China, Eurasia, India, Israel, Japan, South Korea, Singapore, South Africa and in other countries less relevant.

Partner sought

Type and Role of Partner Sought:
They are actively researching partners to support their most advanced specific anti-cancer agent development on the market. They are opened to financial agreement (VC, Bank, Private Investors).
They are also searching for joint venture agreement with companies from the Healthcare sector abroad, with a distribution license agreement eventually.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002001 Bioquímica / biofísica
06001003 Citología, cancerología, oncología
06002009 Diseño molecular
06001015 Productos farmacéuticos / medicamentos